FDA Urges Suspension Of Glaxo's Rotarix Vaccine After PCV-1 Virus Is Detected

The agency plans an advisory committee meeting in four to six weeks and, meanwhile, recommends that Merck's RotaTeq should be used instead.

More from Archive

More from Pink Sheet